Swedbank AB Decreases Stake in United Therapeutics Co. (NASDAQ:UTHR)

Swedbank AB cut its holdings in United Therapeutics Co. (NASDAQ:UTHRFree Report) by 1.8% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 414,937 shares of the biotechnology company’s stock after selling 7,718 shares during the quarter. Swedbank AB owned 0.93% of United Therapeutics worth $148,693,000 as of its most recent SEC filing.

Other institutional investors have also recently modified their holdings of the company. Fisher Asset Management LLC lifted its position in shares of United Therapeutics by 5.8% in the fourth quarter. Fisher Asset Management LLC now owns 3,828 shares of the biotechnology company’s stock valued at $842,000 after acquiring an additional 209 shares in the last quarter. PNC Financial Services Group Inc. increased its stake in United Therapeutics by 6.6% during the fourth quarter. PNC Financial Services Group Inc. now owns 2,636 shares of the biotechnology company’s stock worth $580,000 after acquiring an additional 164 shares during the last quarter. Los Angeles Capital Management LLC increased its stake in United Therapeutics by 21.0% during the first quarter. Los Angeles Capital Management LLC now owns 88,852 shares of the biotechnology company’s stock worth $20,411,000 after acquiring an additional 15,447 shares during the last quarter. Rise Advisors LLC acquired a new stake in United Therapeutics during the first quarter worth about $32,000. Finally, Alaska Permanent Fund Corp boosted its position in shares of United Therapeutics by 263.0% in the first quarter. Alaska Permanent Fund Corp now owns 8,172 shares of the biotechnology company’s stock worth $1,877,000 after buying an additional 5,921 shares during the period. 94.08% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at United Therapeutics

In related news, COO Michael Benkowitz sold 25,000 shares of the business’s stock in a transaction that occurred on Wednesday, August 7th. The shares were sold at an average price of $323.38, for a total value of $8,084,500.00. Following the completion of the transaction, the chief operating officer now owns 2,577 shares in the company, valued at $833,350.26. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. In other news, COO Michael Benkowitz sold 25,000 shares of the stock in a transaction dated Wednesday, August 7th. The shares were sold at an average price of $323.38, for a total transaction of $8,084,500.00. Following the completion of the transaction, the chief operating officer now directly owns 2,577 shares in the company, valued at $833,350.26. This represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Raymond Dwek sold 5,000 shares of the company’s stock in a transaction dated Friday, August 2nd. The shares were sold at an average price of $325.35, for a total transaction of $1,626,750.00. Following the completion of the sale, the director now directly owns 1,750 shares in the company, valued at approximately $569,362.50. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 101,638 shares of company stock valued at $34,431,585. 11.90% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on the company. LADENBURG THALM/SH SH downgraded United Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Thursday, August 1st. Wells Fargo & Company increased their price target on United Therapeutics from $350.00 to $380.00 and gave the company an “overweight” rating in a report on Tuesday, August 20th. TD Cowen increased their price target on United Therapeutics from $270.00 to $350.00 and gave the company a “buy” rating in a report on Thursday, July 11th. Oppenheimer increased their target price on United Therapeutics from $400.00 to $575.00 and gave the stock an “outperform” rating in a report on Wednesday, August 28th. Finally, StockNews.com downgraded United Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Friday, August 2nd. One analyst has rated the stock with a sell rating, three have given a hold rating and eleven have given a buy rating to the stock. Based on data from MarketBeat.com, United Therapeutics currently has an average rating of “Moderate Buy” and a consensus price target of $357.17.

Read Our Latest Research Report on UTHR

United Therapeutics Stock Up 0.7 %

Shares of United Therapeutics stock traded up $2.54 during midday trading on Tuesday, hitting $359.64. The company’s stock had a trading volume of 183,057 shares, compared to its average volume of 471,103. The company has a quick ratio of 4.18, a current ratio of 4.35 and a debt-to-equity ratio of 0.02. United Therapeutics Co. has a 1-year low of $208.62 and a 1-year high of $366.08. The stock has a 50-day simple moving average of $347.35 and a 200-day simple moving average of $305.10. The firm has a market capitalization of $16.00 billion, a P/E ratio of 16.41, a PEG ratio of 1.29 and a beta of 0.57.

United Therapeutics (NASDAQ:UTHRGet Free Report) last posted its earnings results on Wednesday, July 31st. The biotechnology company reported $5.85 earnings per share for the quarter, missing the consensus estimate of $6.33 by ($0.48). The company had revenue of $714.90 million for the quarter, compared to the consensus estimate of $691.87 million. United Therapeutics had a net margin of 40.87% and a return on equity of 18.82%. United Therapeutics’s quarterly revenue was up 19.8% on a year-over-year basis. During the same quarter last year, the business earned $5.24 earnings per share. As a group, sell-side analysts expect that United Therapeutics Co. will post 24.71 earnings per share for the current year.

United Therapeutics Profile

(Free Report)

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.

See Also

Want to see what other hedge funds are holding UTHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for United Therapeutics Co. (NASDAQ:UTHRFree Report).

Institutional Ownership by Quarter for United Therapeutics (NASDAQ:UTHR)

Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.